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Background: Needlestick injuries, mostly due to unsafe needle devices, are a frequent adverse 
event among health care workers and patients on chronic treatment, such as hemophiliacs. To 
improve the safety of these procedures, a needleless reconstitution system, Bio-Set® has been 
implemented for the sucrose-formulated recombinant factor VIII (rFVIII-FS) Kogenate® Bayer 
(Bayer Healthcare, Berlin, Germany). The aim of this study was to collect patients’ satisfaction 
and safety data regarding the administration of rFVIII-FS with this new device.
Methods: This was a multicenter, prospective, postmarketing surveillance study collecting 
data from seven Italian Haemophilia Centers within the framework of an international project 
involving patients from nine European countries. The patients were asked to fill out two prefer-
ence questionnaires (one assessing the old method and one assessing the new method) directly 
after the training and two further preference questionnaries (assessing the new method) after a 
period of about 3 and 12 months.
Results: A total of 44 male hemophilia A patients were included in the analysis. At the end of 
the 12-month observation period, physicians assessed the patients’ satisfaction with Kogenate® 
Bayer with Bio-Set® in 40.9% (n = 18) as “very satisfied” and in 45.5% (n = 20) as “satisfied”, 
whereas “not satisfied” ratings were given for 9.1% (n = 4) of patients (data missing from 
two patients, 4.5%). The compliance of the patients compared with the last method before switch 
to the Bio-Set® device was rated as “better”, “equal”, and “worse” in 72.7% (n = 32), 20.5% 
(n = 9), and 2.3% (n = 1) of patients, respectively. Three patients (6.8%) experienced adverse 
events, but only one event was related to rFVIII infusion (inhibitor development in a patient 
who had little prior exposure to rFVIII) itself and not to the new device per se.
Conclusions: The great majority of Italian patients who switched from an older method of rFVIII 
reconstitution to rFVIII-FS with the new reconstitution method preferred the new method. The 
ease of use, perceived safety from needlesticks, and the speed of reconstitution were identified 
as main advantages by the majority of patients.
Keywords: Kogenate® Bayer, Bio-Set®, hemophilia, therapy, safety
Introduction
Needlestick injuries are frequent adverse events in health care workers worldwide.1–4 Ten 
years ago, the Occupational Safety and Health Administration (OSHA) organization in 
the United States estimated that about 800,000 needlesticks occurred every year among 
American health care workers and most needlestick injuries were due to unsafe needle 
devices rather than due to lack of care. OSHA recommended the introduction of devices 
with incorporated safety features (ie, not just accessories) that would provide a barrier 
between hands and needle, and would remain in place at all times, ie, before disassembly 
and after disposal. The safety system should be simple and easy to operate with little or no International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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training, and should not have a negative impact on the delivery 
of patient care.5 These recommendations were endorsed by the 
US Food and Drug Administration.6 In a study conducted in 
Italy during the period 1995–2004, needlestick exposure was 
reported by 4.9% of health care workers with acute hepatitis B 
and 14.3% of health care workers with acute hepatitis C.7
In view of the frequency of needlesticks among skilled 
health care workers, it is reasonable to assume that the prob-
lem exists also among the caregivers of patients on chronic 
treatment with medicinal products to be administered by 
intravenous route, such as patients with hemophilia A.8 For 
this reason, a needleless reconstitution system, Bio-Set® 
(a trademark of Biodome SAS), has been implemented for 
the sucrose-formulated recombinant coagulation factor VIII 
(rFVIII-FS) Kogenate® Bayer (Bayer Healthcare, Berlin, 
Germany), in which the vial with solvent is replaced by a 
prefilled syringe and the vial containing powder is fitted with 
a self-contained device with protective cap, Bio-Set®.9
An international multicenter postmarketing surveillance 
study was carried out in nine European countries (Austria, 
France, Germany, Greece, Hungary, Italy, Spain, Switzerland, 
and the United Kingdom) to compare the level of satisfaction 
of patients with hemophilia A before and after switching from 
another existing factor VIII reconstitution method to the new 
system with Bio-Set®; In addition, safety and quality of life 
(QoL) data were collected.10 This article describes the results 
obtained in the subset of patients recruited in Italy who were 
observed for a period of 12 months.
Methods
Design of the study
This was the Italian substudy of a prospective, noninterven-
tional, noncontrolled, multicenter postmarketing surveillance 
study carried out at seven hematology centers in Italy. The 
aim was to observe approximately 50 patients with hemo-
philia A, who were going to switch from any other system 
to the reconstitution system with Bio-Set®.
Bio-Set® is a needleless reconstitution device. The 
patients were treated with commercially available product, 
according to the dosage regimen prescribed by the hematolo-
gist. The product was administered via intravenous bolus 
injections using the new system for reconstitution.
The main observation period for each patient started on 
the day they received the instructions and a training on how 
to use the new system and ended after accumulation of a 
minimum of 20 exposure days (ED) with Bio-Set® or after 
3 months (whichever was sooner). The Italian patients were 
subsequently followed-up for another 9 months.
Upon entry into the study, demographic information 
and medical history data were collected using case report 
forms.
Outcome assessments
Patients were asked to complete a 25-item preference 
  questionnaire twice, first assessing the old method and 
then assessing the new one, using a 7-point semiquantita-
tive rating scale for each item which ranged from “strongly 
agree” to “strongly disagree”, directly after training with the 
new method and after a period of about 3 and 12 months. 
Two domains of the preference questionnaire were analyzed 
in addition to the total score: “ease/confidence” (8 items) 
and “worry/safety” (10 items). Patients were also asked to 
indicate their preferred reconstitution method (new method, 
old method, or no preference) for a panel of 8 domains plus 
their overall preference. Additional QoL questionnaires 
could be optionally completed. For adults, the Haemo-QoL-
A questionnaire was used.11 For children aged 4–7 years 
and 8–16 years, two versions of   Haemo-QoL were used.12 
The Haemo-QoL for children consisted of a questionnaire 
to be answered by the children themselves and a second 
  questionnaire to be answered by their parents. However, the 
interpretation of the results was not possible due to the low 
number of questionnaires completed.
At the end of the main study period as well as at the end 
of the follow-up period, the hematologists also analyzed 
exposure to rFVIII-FS, enquired about adverse events, and 
assessed patient satisfaction of the new system with   Bio-Set® 
using a 3-item semiquantitative rating scale, as well as com-
pliance compared with the old method.
statistical analysis
All patients who received training with the new system and 
completed at least one preference questionnaire were included 
in the descriptive statistical analysis. Descriptive analyses of 
the data were performed using summary statistics for categori-
cal and quantitative data. Incidence rates for specific events 
were calculated as the number of specific events reported 
divided by the number of patients at risk, where the number of 
specific events was defined as the number of patients report-
ing the specific event and the number of patients at risk was 
defined as total number patients exposed to rFVIII-FS during 
the observation period. For multiple occurrences of a specific 
event within one patient, the event was counted only once. 
Regarding patient preference, item responses were trans-
formed into scores using 0–100 scales to calculate the scores 
of the domains “ease/confidence” and “worry/safety”.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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The study was conducted according to Italian and 
  European regulations related to observational postmarketing 
studies; the study was approved by an appropriate Ethics 
Committee and all the patients or their parents gave their 
informed consent in writing.
Results
study population
During the period November 2005–July 2007, a total of 
45 patients entered the Italian substudy and 44 were   evaluable 
for the descriptive statistical analysis. Their main   demographic 
and baseline characteristics are shown in Table 1. All patients 
were Caucasian males, except one, who was Asian, and nearly 
half of the patients (45.5%, n = 20) were aged up to 18 years 
old; except for one elderly patient (older than 65 years), all 
remaining patients were young or middle-aged adults.
For most of the patients, the diagnosis of hemophilia A 
was known for more than 10 years (n = 32, 72.7%). Most of 
the patients suffered from severe hemophilia A (,1% FVIII 
activity; n = 33, 75%) and had a history of extensive exposure 
to FVIII (.150 days; n = 35, 79.5%). Few patients had a his-
tory of inhibitors to FVIII (n = 5, 11.4%) or actually suffered 
from an inhibitor to FVIII at enrollment (n = 2, 4.5%).
More than one-third of the patients (n = 16, 36.4%) had 
a known family history of hemophilia A; the affected family 
members were brothers and uncles (n = 6, 37.5% each) or 
grandfathers (n = 4, 25.0%).
Although data were missing for one patient, 43 patients 
were on treatment with rFVIII-FS and treatment was self-
administered by 31.8% of patients (n = 18) at study start.
Treatment
On average, 30.0 ± 9.6 IU/kg (range, 15–60 IU/kg) were given 
for prophylaxis to more than half of the patients (26 patients, 
59.1%) either 2 or 3 times a week. On-demand treatment 
was reported for 36.4% of patients (n = 16), who took on 
average 31.7 ± 7.6 IU/kg (range, 25–40 IU/kg). Further, two 
patients underwent an immune tolerance induction or inhibi-
tor adapted therapy during the study.
Patient preference
Overall, patient preference was in favor of the new   system 
immediately after training: 77.3% (n = 34) preferred   Bio-Set®, 
6.8% (n = 3) preferred the old method, and 15.9% (n = 7) had 
no preference. After 3 months of experience with the new sys-
tem (or at least 20 days of exposure), the proportion of patients 
increased to 85.7% (n = 36) and after 12 months up to 88.4% 
(n = 38). Immediately after   training, the main reason for the 
preference was safety from needlesticks (90.9%), followed 
by convenience for traveling (79.5%), ease of use (77.3%), 
and amount of waste (72.7%), whereas after 12 months of 
experience, the main reasons shifted to speed of reconstitution 
(90.7%) and convenience for traveling (88.4%), followed by 
safety from needlesticks (83.7%), ease of use (83.7%), and 
ease of learning (83.7%; Figure 1A and 1B).
Patient preference was in favor of the new reconstitution 
system also in terms of mean total preference score: immedi-
ately after training, it was 61.3 ± 14.1 for the old method vs 
Table 1 Demographic and baseline characteristics of the study 
population
Characteristic n (%) patients (N = 44)
race 
  caucasian 
  Asian
 
43 (97.7) 
1 (2.3)
Age (years) 
  ,2 
  $2 #12 
  .12 #18 
  .18 #40 
  .40 #65 
  .65
 
2 (4.5) 
11 (25.0) 
7 (15.9) 
19 (43.2) 
4 (9.1) 
1 (2.3)
Time since diagnosis (years) 
  ,1 
  1–5 
  6–10 
  .10
 
2 (4.5) 
6 (13.6) 
4 (9.1) 
32 (72.7)
FVIII activity (%) 
  ,1 
  1–2 
  .2–5 
  .5
 
33 (75.0) 
2 (4.5) 
6 (13.6) 
3 (6.8)
estimated number of eD before enrollment 
  #20 
  21–50 
  51–100 
  101–150 
  .150 
  Missing
 
2 (4.5) 
2 (4.5) 
0 
4 (9.1) 
35 (79.5) 
1 (2.3)
history of FVIII inhibitors 5 (11.4)
FVIII inhibitors at study start 2 (4.5)
Administration 
  Patient 
  Parents 
  health care professionals 
  Patient + parents 
  Patient + health care professionals 
  Parents + health care professionals 
  Missing
 
14 (31.8) 
10 (22.7) 
12 (27.3) 
1 (2.3) 
3 (6.8) 
2 (4.5) 
2 (4.5)
Type of treatment 
  Prophylaxis 
  On-demand 
  Othera
 
26 (59.1) 
16 (36.4) 
2 (4.5)
Notes: aImmune tolerance induction or inhibitor adapted therapy.
Abbreviation: eD, exposure day. International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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77.0 ± 13.7 for the new method; the score increased over time 
to 81.5 ± 10.4 after 12 months. Domain analysis   disclosed 
a much greater difference between the two methods in the 
domain “worry/safety” than in the domain “ease/  confidence”: 
immediately after training, the mean preference score related 
to “worry/safety” for the old method was 50.2 ± 17.2 vs 
76.4 ± 13.2 for the new one, whereas the mean perference 
score related to “ease/confidence” was 70.2 ± 16.4 for the old 
method vs 78.3 ± 15.2 for the new one. The preference scores 
increased slightly after gaining experience: the worry/safety 
score increased up to 79.1 ± 12.1 and the ease/confidence 
score up to 83.4 ± 12.9 after 12 months. The course of the 
differences in median scores is illustrated in Figure 2.
Regarding individual items, the preference score was 
consistently in favor of the new reconstitution system with 
Bio-Set®.
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Figure 1 A) Preference immediately after training. B) Preference after 12 months.
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satisfaction and compliance
After 3 months, 88.6% of patients were at least satisfied with 
the new system (n = 39) and 6.8% (n = 3) were not. Informa-
tion on this question was missing for two patients (4.5%). 
The satisfaction rate was similar after 12 months (86.4% very 
satisfied or satisfied, 9.1% not satisfied, information missing 
from two patients).
Compared with the last method before switch, compli-
ance was rated as “better” with the new method than with 
the old method in 63.6% (n = 28) of patients, “equal” in 
27.3% (n = 12), and “worse” in 4.5% (n = 2) at 3 months; 
this   information was missing from two patients (4.5%). At 
12 months, compared with the last method, compliance was 
rated as “better” than the old method in 72.7% (n = 12), 
“equal” in 20.5% (n = 5), and “worse” in 2.3% (n = 1;   missing 
data 4.5%, n = 2).
safety
Although three patients (6.8%) experienced adverse events, 
two of these were considered unrelated to study medication, 
but all three adverse events were considered not related to 
the new device.
A 2-year-old boy with a known diagnosis of severe hemo-
philia A, who had already been exposed to rFVIII-FS before 
the study for about 20 days, developed inhibitor antibodies 
(high titer, 34 BU) after about 5 months (total EDs, 12); 
treatment with rFVIII-FS was continued. An human immuno-
deficiency virus-positive 41-year-old man with concomitant 
hepatitis died on account of carcinoma of the liver; the death 
was considered not to be related to rFVIII-FS. A 30-year-
old man reported musculoskeletal pain in his ankle, which 
resolved after 6 days; it was considered not to be related to 
rFVIII-FS, which was continued.
Discussion
In a previous study, Butler et al8 showed that patients, caregiv-
ers, and nurses preferred the Bio-Set® method compared with 
the conventional 2-vial transfer needle reconstitution method 
with regard to worry/safety, ease/confidence, and overall pref-
erence. In addition, time savings have been associated with 
Bio-Set® use compared with the conventional reconstituion 
method in another study.13
This postmarketing surveillance study, which evaluated 
patients’ longer-term satisfaction, suggests that enrolled 
patients prefer the new system with Bio-Set® to the old 
reconstitution method, mainly in view of its perceived safety 
regarding the prevention of needlesticks and its convenience 
in terms of speed of reconstitution and reduced medical 
waste. In addition, the smaller package size was also preferred 
because it simplifies aspects of patients’ daily lives such as 
traveling. This study also suggests that the new reconstitution 
method is safe, as the only adverse reaction reported to be 
related to study medication was the development of FVIII 
inhibitors, which is a well-known complication of first expo-
sures to rFVIII therapy early in childhood and obviously not 
related to the use of the reconstitution device.
The strength of the study is that it reflects clinical reality, 
since it was an observational study, and the patient population 
was a representative sample of the patients seen in clinics in 
Italy, both in terms of age (all age groups were included), and 
in terms of the severity of the disease (most of the patients 
attending hemophilia centers in Italy have severe disease as was 
Figure 2 Median preference scores over time.
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the case in this study where approximately 75% of the patients 
had severe hemophilia). Moreover, the sample was quite large, 
considering that it was a national substudy (n = 44 patients).
This study is limited by the lack of a control group and the 
fact that all patients but one switched from rFVIII-FS with the 
prior reconstitution method, not from a variety of products.
Conclusion
This postmarketing surveillance study indicates that the new 
system with Bio-Set® is a safe method for the reconstitu-
tion of rFVIII-FS that patients prefer to the prior one. This 
new reconstitution method could improve patients’ compli-
ance with therapy, especially for those receiving long-term 
prophylaxis treatment.
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